GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Krystal Biotech Inc.
The shares of Krystal Biotech, a company developing gene therapy for skin diseases, are highly volatile. Their price depends on the commercial success of its first approved drug and news about clinical trials of other products in its portfolio.
Share prices of companies in the market segment - Pharma skin
Krystal Biotech is a biopharmaceutical company focused on gene therapy for rare skin diseases. We classify it as part of the Pharma Skin sector, and the chart below shows the dynamics of this segment as a whole, reflecting trends in this field of medicine.
Broad Market Index - GURU.Markets
Krystal Biotech is a biotech company that developed the world's first approved gene therapy for the treatment of epidermolysis bullosa, a rare skin disease. As a pioneer in its field, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Krystal's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
KRYS - Daily change in the company's share price Krystal Biotech Inc.
The daily price change of Krystal Biotech, a company focused on gene therapy for skin diseases, reflects the high volatility of the biotech sector. Change_co is the market's immediate reaction to news about clinical trials. This metric is essential for building risk models for innovative companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma skin
Krystal Biotech, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with KRYS, whose success hinges on the approval and launch of its gene therapy for skin diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Krystal Biotech is a biopharmaceutical company pioneering gene therapy for skin diseases. The biotech sector is extremely volatile, and Krystal's story is a prime example. The chart below reflects the industry's average price movements, providing context for Krystal's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Krystal Biotech Inc.
Krystal Biotech achieved a breakthrough last year, receiving FDA approval for its first drug—a gene therapy for a rare skin disease. Its year-over-year stock price performance, shown in the chart, directly reflects this achievement.
Annual dynamics of market capitalization of the market segment - Pharma skin
Krystal Biotech, Inc. is a biotech company pioneering gene therapy for skin diseases. The approval of its first-of-its-kind drug was a breakthrough. This chart will show how the market views the commercial potential of its unique platform and its progression to commercialization.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Following the successful launch of its gene therapy drug, Krystal Biotech is in a phase of rapid commercial growth. Its stock price is driven by the rapid adoption of the new drug by doctors and patients. This chart tells the story of the biotech startup's transformation into a fully-fledged commercial company.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Krystal Biotech Inc.
Krystal Biotech, a biotech company that developed the first gene therapy for a rare skin disease, has sharp monthly fluctuations reflecting the commercial success of its first drug and news about the development of other gene therapies using its platform.
Monthly dynamics of market capitalization of the market segment - Pharma skin
This chart reflects the dynamics of the biotech sector. For Krystal, with its breakthrough gene therapy for skin, it's the backdrop. Its outpacing the sector demonstrates how a successful launch of a first-in-class drug can radically change a company's trajectory.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Krystal Biotech is a biopharmaceutical company that went commercial after the approval of its gene therapy for a rare skin disease. This full-market performance chart allows us to assess how Krystal's shares are performing after transitioning from risky development to commercial growth, and how its unique product allows it to defy overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Krystal Biotech Inc.
Krystal Biotech is a biotech company developing gene therapy for skin diseases. Its weekly stock price is extremely volatile, depending on news about clinical trials and FDA decisions. This chart tells the story of how a scientific breakthrough can radically change a company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma skin
Krystal Biotech is part of the volatile biotech sector, where sentiment can shift across the entire industry. Important FDA decisions or scientific breakthroughs can lift or derail the entire segment. The chart shows how the company compares to the overall biotech industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Krystal Biotech is a biopharmaceutical company that has developed gene therapy for skin. Its shares follow the rhythm of sales and new development news. The chart will show how its weekly performance is detached from overall market trends, driven by its own unique growth drivers.
Market capitalization of the company, segment and market as a whole
KRYS - Market capitalization of the company Krystal Biotech Inc.
Krystal Biotech's market capitalization is a visual representation of the promise of gene therapy for rare skin diseases. The chart shows how the market values the commercial launch of the company's first approved drug and the potential of its platform for developing new drugs.
KRYS - Share of the company's market capitalization Krystal Biotech Inc. within the market segment - Pharma skin
Krystal Biotech is a biopharmaceutical company that pioneered the use of gene therapy to treat skin diseases. Its share of its segment's market capitalization reflects the commercial success of its first approved drug. The chart tells the story of how an innovative platform can quickly transform a company's market share.
Market capitalization of the market segment - Pharma skin
Krystal Biotech is a pioneer in developing gene therapy for skin diseases. How big is this arena? The chart below shows the overall market capitalization of the pharmaceutical sector. Its growth reflects the potential of the company, whose first drug was a breakthrough in the treatment of the rare epidermolysis bullosa, and its ambitions in dermatology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Krystal Biotech's chart illustrates a breakthrough in gene therapy for skin diseases. Its market cap soared after the approval of the world's first locally developed gene therapy. The chart's dynamics are a clear example of how successful application of an innovative platform can create a multi-billion-dollar company.
Book value capitalization of the company, segment and market as a whole
KRYS - Book value capitalization of the company Krystal Biotech Inc.
For Krystal Biotech, which develops gene therapy for skin diseases, book value is its tangible foundation: production facilities for vector creation, laboratories, and financial reserves. The chart below shows how the company built its physical foundation to bring innovative products to market.
KRYS - Share of the company's book capitalization Krystal Biotech Inc. within the market segment - Pharma skin
Krystal Biotech is a pioneer in skin gene therapy, and its tangible assets include its own state-of-the-art manufacturing facilities (GMP). These sterile facilities, capable of producing viral vectors, are its key competitive advantage. The chart shows the company's control over this unique biotech infrastructure.
Market segment balance sheet capitalization - Pharma skin
Krystal Biotech is a biopharmaceutical company with its own manufacturing facility, making it more capital-intensive than pure R&D startups. The chart below illustrates the scale of the entire pharmaceutical sector, providing context for assessing its integrated model.
Book value of all companies included in the broad market index - GURU.Markets
Krystal Biotech is a pioneer in gene therapy for skin diseases. Its assets include laboratories and manufacturing facilities. A modest stake in BCap_All provides the material foundation for a technology that could offer revolutionary treatments for rare and severe skin diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Krystal Biotech Inc.
Krystal Biotech is a gene therapy company. Its balance sheet is its laboratories. Its market valuation is tens of times higher. This premium is the price paid for its approved drug, Vyjuvek, which is the first of its kind. The P/B here is the valuation of a scientific victory already achieved.
Market to book capitalization ratio in a market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapies for skin diseases. Its value is based almost entirely on its scientific platform. The chart shows the significant premium to book value that investors are paying for the potential of its innovative treatments.
Market to book capitalization ratio for the market as a whole
Krystal Biotech is a biotech company that developed and commercialized the world's first topical gene therapy for a rare skin disease. Compared to average market valuations, as shown in this chart, its substantial premium reflects the success of its scientific platform and its potential for application to other diseases.
Debts of the company, segment and market as a whole
KRYS - Company debts Krystal Biotech Inc.
Krystal Biotech, a biotech company using herpes simplex virus-based gene therapy to treat skin diseases, finances its cutting-edge research with leverage. The debt burden reflects the cost of clinical trials and bringing a first-of-its-kind drug to market, which requires significant investment before revenue can be generated.
Market segment debts - Pharma skin
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases. Its platform delivers therapeutic genes directly into skin cells. This chart shows how the company is funding its cutting-edge, yet expensive, research as it approaches the potential commercialization of its unique drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Krystal Biotech Inc.
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases. Having recently received approval for its first product, the company is moving from R&D to commercialization. This timeline will show how its financial structure is evolving, and whether it will use debt to fund production and marketing.
Market segment debt to market segment book capitalization - Pharma skin
Krystal Biotech is developing gene therapy for rare skin diseases. This chart shows the collective debt burden in the cutting-edge gene therapy sector. It provides insight into how the industry as a whole finances its expensive and time-consuming research, and how Krystal's financial strategy for commercialization compares against this backdrop.
Debt to book value of all companies in the market
Krystal Biotech, a gene therapy company, requires significant capital for R&D. This chart shows the overall level of debt in the market, reflecting investors' willingness to finance risk. For Krystal, this provides an important context for how easy it is to raise funds for innovative but risky projects.
P/E of the company, segment and market as a whole
P/E - Krystal Biotech Inc.
Krystal Biotech, Inc. is a biotech company developing gene therapies for rare skin diseases. This chart shows that the company's valuation is based on the success of its first commercial drug and the potential of its platform. Investors are betting that its unique treatment approach will transform patients' lives.
P/E of the market segment - Pharma skin
Biotechnology, especially gene therapy like Krystal Biotech's, is at the cutting edge of science. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Krystal, with its already approved product, is valued based on both current sales and the potential of its platform to treat other rare diseases.
P/E of the market as a whole
Krystal Biotech is a biotech company that developed and commercialized the world's first gene therapy for a rare genetic skin disease. Its valuation now hinges on the successful launch of the drug and the development of other programs. Overall market sentiment, reflected in this chart, is completely irrelevant to the company compared to sales data and new research results.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Krystal Biotech Inc.
Krystal Biotech is a biotech company that developed and commercialized the world's first gene therapy for a rare genetic skin disease. This chart reflects analyst expectations regarding the commercial success of this breakthrough drug and the potential of its technology platform for developing other treatments.
%20P%2FE%20Krystal%20Biotech%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Krystal-Biotech-Inc.&v=1772620380865 "Chart of the company's future (projected) P/E Krystal Biotech Inc.")
Future (projected) P/E of the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapies for skin diseases. This chart compares its future profitability expectations with the biotech sector. It demonstrates the level of investor confidence in its innovative platform for delivering therapeutic genes directly to the skin and the commercial success of its first approved drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772620380888 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases. This chart shows the company's overall risk appetite. Krystal's success depends on scientific breakthroughs and regulatory approvals. A positive market environment facilitates capital raising but is no substitute for fundamental scientific advances.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772620380950 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Krystal Biotech Inc.
Krystal Biotech is a biotech company developing and commercializing gene therapy for rare skin diseases. This chart shows the company's financial journey from clinical development to the launch of its first-of-its-kind drug. The trend reflects sales volumes and ongoing investments in expanding the gene therapy platform.
Profit of companies in the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases. Its platform enables the delivery of therapeutic genes directly into patients' cells. This chart illustrates the financial climate in the dermatological pharmaceutical sector, highlighting the commercial potential of innovative skin treatments.
Overall market profit
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases. Its value is determined by the clinical and commercial success of its drugs. The company's business is entirely dependent on science and medicine, not economic cycles, making it immune to the fluctuations shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Krystal Biotech Inc.
Krystal Biotech is a biotech company that has secured approval for the world's first gene therapy for a rare and severe skin disease. Its future now hinges on the commercial success of this breakthrough drug. This chart shows how analysts are modeling its adoption rate and future revenue.
%20profit%20of%20the%20company%20Krystal%20Biotech%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Krystal-Biotech-Inc.&v=1772620381099 "Graph of future (projected) profit of the company Krystal Biotech Inc.")
Future (predicted) profit of companies in the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapy for skin diseases using a modified herpes simplex virus as a drug delivery vector. This chart shows forecasts for the biotech sector. The recent approval of its first drug for a rare genetic skin disorder completely changes the company's outlook.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772620381116 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
Krystal Biotech is a biotech company developing gene therapy for skin diseases. Its success is determined by the results of clinical trials. However, this expected corporate earnings schedule is important. It influences the investment climate. During periods of earnings growth, investors are more inclined to fund high-risk but potentially breakthrough projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772620381169 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Krystal Biotech Inc.
Krystal Biotech is developing gene therapy for rare skin diseases. This chart shows how the company's valuation depends on the commercial success of its first approved drug and the potential of its technology platform. It reflects investor expectations for future sales growth in this innovative field.
P/S market segment - Pharma skin
Krystal Biotech is a biotech company that has developed a gene therapy platform for skin diseases. Its first commercial product is designed to treat epidermolysis bullosa. This chart reflects how the market values biotech companies, helping to understand how highly investors value Krystal's innovative platform and its commercial potential.
P/S of the market as a whole
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases. Its first drug has already been approved, driving growing revenue. This average market valuation chart shows how investors view the company's real revenue as it successfully navigates the path from development to commercialization of a breakthrough drug.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Krystal Biotech Inc.
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases. This chart shows investor expectations for future revenue, which hinge on the commercial success of its first approved drug and the potential of its platform to develop new drugs for other diseases.
%20P%2FS%20Krystal%20Biotech%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Krystal-Biotech-Inc.&v=1772620381231 "The graph of the company's future (projected) P/S Krystal Biotech Inc.")
Future (projected) P/S of the market segment - Pharma skin
Krystal Biotech has developed and commercialized the world's first gene therapy for a rare skin disease. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of the commercial success of this breakthrough drug and the potential of the company's entire technology platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772620381255 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases based on its innovative platform. This chart reflects confidence in future growth, and Krystal Biotech is an example of its source. The company's success in creating a "drug in a tube" could revolutionize dermatology and create a new market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772620381320 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Krystal Biotech Inc.
Krystal Biotech is a commercial gene therapy company. It received approval for its first drug, tópico, for the treatment of a rare genetic skin disease. This chart shows the sales revenue of this innovative product, reflecting its successful market launch and acceptance by physicians.
Sales of companies in the market segment - Pharma skin
Krystal Biotech is the first biotech company in the world to receive commercial approval for gene therapy for skin diseases. Their success with Vyjuvek ushers in a new era in dermatology. This graph illustrates the potential of gene therapy, where Krystal's breakthrough could become a platform for treating numerous other rare diseases.
Overall market sales
Krystal Biotech, Inc. is at the forefront of gene therapy for rare skin diseases. The company's success depends on scientific breakthroughs and access to capital. Periods of revenue growth, reflected in this chart, create a favorable investment climate. Investors are more willing to fund innovative biotech companies, allowing Krystal to advance its research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Krystal Biotech Inc.
Krystal Biotech is a biotechnology company developing gene therapy for skin diseases. Its future sales forecast is based on the expected commercial success of its first approved drug for a rare genetic skin disorder. This demonstrates the market's confidence in the potential of its innovative drug discovery platform.
%20sales%20of%20the%20company%20Krystal%20Biotech%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Krystal-Biotech-Inc.&v=1772620381397 "Schedule of future (projected) sales of the company Krystal Biotech Inc.")
Future (projected) sales of companies in the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases. Its platform enables the delivery of therapeutic genes directly into patients' cells. This graph shows forecasts for the pharmaceutical sector, allowing one to assess how Krystal's innovative approach could transform the treatment of dermatological diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772620381407 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
Krystal Biotech, a company working on gene therapy for skin diseases, sees this chart as a marker of the biotech investment climate. The positive economic forecasts reflected here encourage capital inflows into the industry and the healthcare system's readiness to cover the costs of innovative, breakthrough treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772620381423 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Krystal Biotech Inc.
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases. After receiving approval for its first drug, the company moved from research to commercialization. This chart shows how sales are progressing and how revenue is starting to convert into net profit, covering years of R&D investment.
Market segment marginality - Pharma skin
Krystal Biotech is a biotech company specializing in gene therapy for rare dermatological diseases. This chart shows its financial performance. Following the recent approval of its first drug, the company's profitability should increase sharply as it begins to generate sales revenue, potentially putting it well ahead of other biotechs in development.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Krystal Biotech Inc.
Krystal Biotech is a biopharmaceutical company developing gene therapies for rare skin diseases. This chart shows the growth of its scientific and clinical teams. This increase in staff directly reflects progress toward commercializing its innovative gene delivery platform.
Share of the company's employees Krystal Biotech Inc. within the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases using its herpes virus-based platform. This chart shows the percentage of all scientists working in this narrow and cutting-edge field that Krystal has. This reflects its scientific potential and leadership in dermatological gene therapy.
Number of employees in the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases. Its staff consists of highly qualified scientists and clinicians. The graph demonstrates the team's growth, directly reflecting progress in the development and preparation for commercialization of its innovative drugs.
Number of employees in the market as a whole
Krystal Biotech is a biotech company developing gene therapy for rare skin diseases. Its growth depends solely on scientific advances and regulatory approvals. Unlike the overall labor market dynamics shown in this chart, hiring at Krystal represents an investment in breakthrough medical technologies that can change the lives of patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Krystal Biotech Inc. (KRYS)
Krystal Biotech is a biotech company that developed the world's first topical gene therapy. Its enormous market capitalization, despite its small staff, reflects the market's valuation of its breakthrough technology. This chart shows the astronomical cost per employee, reflecting the value of their unique scientific achievements.
%20of%20the%20company%20Krystal%20Biotech%20Inc.%20(KRYS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Krystal-Biotech-Inc.-KRYS&v=1772620381546 "Chart of market capitalization per employee (in thousands of dollars) of the company Krystal Biotech Inc. (KRYS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
Krystal Biotech is a biotech company that developed the first FDA-approved gene therapy (Vyjuvek) for the treatment of epidermolysis bullosa (butterfly babies). This chart shows the average capitalization per employee in the sector, demonstrating how much the market values their unique gene therapy platform.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772620381596 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
Krystal Biotech is a biotech company developing gene therapy for skin diseases. Its valuation is based on the potential of its innovative platform. This chart illustrates the enormous value the market places on a small team of scientists whose developments could radically change approaches to treating dermatological diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772620381598 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Krystal Biotech Inc. (KRYS)
Krystal Biotech (KRYS) is a biotech company that developed the first approved gene therapy for the treatment of "butterfly babies" (epidermolysis bullosa). This chart shows the explosive impact of the approval, demonstrating how a small team of scientists and a commercial arm can generate enormous profits from a single breakthrough, ultra-expensive drug.
%20Chart%20Krystal%20Biotech%20Inc.%20(KRYS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Krystal-Biotech-Inc.-KRYS&v=1772620381604 "Company Profit Per Employee (in thousands of dollars) Chart Krystal Biotech Inc. (KRYS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
Krystal Biotech (KRYS) is a biotech company with an approved "gene therapy" (herpes-based) "gel" for the treatment of "butterfly skin." This chart shows the benchmark for "Pharma skin" (Biotech). In this R&D sector, the benchmark is *astronomically* high. This is the "blockbuster business," where a single patent for an "orphan" drug can generate billions.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772620381616 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
Krystal Biotech (KRYS) is a biotech company specializing in gene therapy for rare dermatological diseases. Their platform uses a modified herpes virus for gene delivery. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772620381618 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Krystal Biotech Inc. (KRYS)
Krystal Biotech is a biotech company developing gene therapies for rare skin diseases. This chart is a commercialization story. After the approval of their first drug, it shows how a small team can generate significant revenue by offering revolutionary treatment to patients who previously had no options.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Krystal-Biotech-Inc.-KRYS&v=1772620381624 "Sales chart per company employee Krystal Biotech Inc. (KRYS)")
Sales per employee in the market segment - Pharma skin
Krystal Biotech is a biotech company developing gene therapy for skin diseases using a viral vector. This chart shows the average revenue per employee in the sector. For biotech companies at the commercialization stage, this is an important indicator of the productivity of their scientific platform and sales team.
Sales per employee for the market as a whole
Krystal Biotech, Inc. is a biotech company that commercialized the first gene therapy for "butterfly babies." This is a breakthrough in medicine. This chart reflects their transition from R&D to a commercial company. It shows how efficiently they are selling their innovative and very expensive drug (Vyjuvek) per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Krystal Biotech Inc. (KRYS)
Krystal Biotech is a biopharmaceutical company focused on gene therapy for rare skin diseases. Its first drug (Vyjuvek) for "butterfly babies" has been approved. The chart shows investor skepticism about the drug's commercial success. They are betting that the market will be very small or that the company will be unable to bring other products to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Krystal-Biotech-Inc.-KRYS&v=1772620381647 "Short Shares Chart for the Company Krystal Biotech Inc. (KRYS)")
Shares shorted by market segment - Pharma skin
Krystal Biotech is a biotech company that developed the first gene therapy for the treatment of "butterfly babies" (epidermolysis bullosa). This chart reflects the overall pessimism in biotech. It shows the general skepticism of investors: they may be concerned not only about the commercial launch of KRYS but also about regulatory issues with gene therapy in general.
Shares shorted by the overall market
Krystal Biotech (KRYS) is a biotech focused on gene therapy. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs dependent on financing. This pessimism, visible on the chart, threatens the capital needed for KRYS.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Krystal Biotech Inc. (KRYS)
Krystal Biotech is a biotech company that received approval for a gene therapy for a rare skin disease. The stock is volatile. A chart above 70 could reflect post-approval euphoria or a strong launch. A chart below 30 could reflect concerns about sales, competition, or R&D setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Krystal-Biotech-Inc.-KRYS&v=1772620381689 "RSI 14 indicator chart for the company's stock Krystal Biotech Inc. (KRYS)")
RSI 14 Market Segment - Pharma skin
Krystal Biotech is a biotech company that has developed a gene therapy platform for treating dermatological diseases. Their first approved drug, Vyjuvek, treats epidermolysis bullosa. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Krystal stands out.
RSI 14 for the overall market
Krystal Biotech is a biotech company that developed the first approved gene therapy for a rare skin disease. This is breakthrough science. This chart shows the overall risk appetite in biotech. In times of panic, investors can sell off even companies with approved products, fearing competition or a slow start to sales.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KRYS (Krystal Biotech Inc.)
Krystal Biotech (KRYS) is a biotech company specializing in gene therapy for rare skin diseases. This chart shows the average analyst price target, reflecting their high confidence in the commercial success of the approved drugs and the potential of the company's research platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KRYS-Krystal-Biotech-Inc.&v=1772620381719 "A chart showing analyst consensus forecasts for the expected stock price. KRYS (Krystal Biotech Inc.)")
The difference between the consensus estimate and the actual stock price KRYS (Krystal Biotech Inc.)
Krystal Biotech is a biotech company pioneering gene therapy for rare dermatological diseases. This chart shows the gap between the market's current valuation of KRYS and analysts' perceptions of its value. This reflects their opinion of the commercial potential of their innovative platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KRYS-Krystal-Biotech-Inc.&v=1772620381733 "A chart showing the difference between the consensus forecast and the actual stock price. KRYS (Krystal Biotech Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
Krystal Biotech (KRYS) is a biotech company that developed and commercialized the first "gene therapy" for skin using a viral vector (herpes). This chart shows the overall expectations of analysts in the pharmaceutical sector. It reflects whether experts believe in the commercial success of this innovative platform.
Analysts' consensus forecast for the overall market share price
Krystal Biotech (KRYS) is a biotech company that developed the first gene therapy to treat butterfly children (epidermolysis bullosa). This chart of overall market sentiment is important. Optimism = the market is willing to fund expensive R&D and believe in the future of gene therapy. Pessimism = risk aversion from unprofitable biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Krystal Biotech Inc.
Krystal Biotech is a biotech company that has achieved success in gene therapy for skin diseases. Their flagship product is the world's first approved treatment for butterfly children (epidermolysis bullosa). This chart is an evaluation of their unique R&D platform. It reflects the commercial launch of their first drug and the potential of their technology for treating other diseases.
AKIMA Market Segment Index - Pharma skin
Krystal Biotech (KRYS) is a pioneer in gene therapy for the skin; the company developed the world's first approved drug (Vyjuvek) for the treatment of a rare genetic skin disorder (epidermolysis bullosa). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Krystal's breakthrough platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Krystal Biotech is a biotech company that writes on skin. Its breakthrough gene therapy (Vyjuvek) treats a rare and severe skin disease (butterfly babies). It's a breakthrough scientific story. This chart, reflecting the market average, is the backdrop. It helps assess how this innovative biotech company stacks up against the backdrop of overall economic trends.
